ImmunAbs
ImmunAbs is a clinical-stage biotech company established by experts in global standard antibody therapeutics development. ImmunAbs has 20 years of experience in developing best-in-class monoclonal antibodies using technologies such as phage display and single B cell cloning to obtain humanized antibodies from immunized animal species. Our lead pipeline is currently in a phase 1 clinical trial in the US and will move forward to a phase 2a clinical trial in 2024.
Location: Korea